Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, … Read more
Oryzon Genomics S.A (ORYZF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: -0.015x
Based on the latest financial reports, Oryzon Genomics S.A (ORYZF) has a cash flow conversion efficiency ratio of -0.015x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.19 Million) by net assets ($79.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oryzon Genomics S.A - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Oryzon Genomics S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oryzon Genomics S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oryzon Genomics S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NITTETSU MNG CO.LTD
F:7GI
|
N/A |
|
Trifork Holding AG
CO:TRIFOR
|
0.053x |
|
Wereldhave Belgium Naamloze vennootschap
F:WPU
|
0.019x |
|
Wuhan Citms Technology Co Ltd
SHG:688038
|
-0.054x |
|
Jiujiang Shanshui Technology Co.Ltd
SHE:301190
|
-0.002x |
|
Weyco Group Inc
NASDAQ:WEYS
|
0.100x |
|
Long Chen Paper Co Ltd
TW:1909
|
0.030x |
|
Rain Industries Limited
NSE:RAIN
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Oryzon Genomics S.A (2014–2024)
The table below shows the annual cash flow conversion efficiency of Oryzon Genomics S.A from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $87.04 Million | $-5.69 Million | -0.065x | -829.69% |
| 2023-12-31 | $81.77 Million | $-574.96K | -0.007x | +72.38% |
| 2022-12-31 | $72.57 Million | $-1.85 Million | -0.025x | +49.97% |
| 2021-12-31 | $71.26 Million | $-3.63 Million | -0.051x | +19.79% |
| 2020-12-31 | $75.93 Million | $-4.82 Million | -0.063x | +1.42% |
| 2019-12-31 | $61.13 Million | $-3.93 Million | -0.064x | -335.99% |
| 2018-12-31 | $45.13 Million | $-666.09K | -0.015x | +89.20% |
| 2017-12-31 | $34.43 Million | $-4.71 Million | -0.137x | +37.94% |
| 2016-12-31 | $22.73 Million | $-5.01 Million | -0.220x | -1262.00% |
| 2015-12-31 | $27.59 Million | $523.14K | 0.019x | -97.83% |
| 2014-12-31 | $13.89 Million | $12.13 Million | 0.873x | -- |